Sin conexión a internet: se muestra la versión guardada de la página.

Fortress Biotech…

USUSD
← Al screener

Fortress Biotech Inc (US:FBIO) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 1. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la empresa

Sitio web
fortressbiotech.com
Relaciones con los inversores
fortressbiotech.com/investors
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Sede central
BAY HARBOR ISLANDS, United States
Consejero delegado
Lindsay Allan Rosenwald
Empleados
34
Fundada
2006
Acciones en circulación
33.35 M
Capital flotante
21.44 M
Capitalización bursátil
73.37 M USD
Insiders
22.7%
Inversores institucionales
31.43%
Industria (SIC)
Pharmaceutical Preparations
LEI
529900DZUWSYUURECK24
Ratio de reparto
0.4%
FCF
—
Deuda
35.0 M USD
caja neta
Racha de dividendos
—
Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
Descripción

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Bolsas y tickers

BolsaTickerMonedaPrecioTipo
US USA StocksFBIOUSD2.09 +2.45%acciones ordinarias

Precio en 3 meses

US:FBIO · USD
día alcista día bajista fecha ex-dividendo fecha de pagoPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Dividendos

No se han encontrado pagos de dividendos (comprobado el 11.10.2026). Es probable que la empresa no reparta dividendos.

Noticias de esta semana

No hay noticias en la última semana. Últimas noticias: 08.09.2026.

anuncio

Principales accionistas

TitularParticipaciónAccionesFecha del informe
ROSENWALD LINDSAY A (Chi…≈13.74%4.59 M2026-03-18
WEISS MICHAEL S (Officer…≈6.82%2.28 M2026-03-18
JIN DAVID (Chief Financi…≈4.95%1.65 M2026-06-22
Vanguard Capital Managem…3.11%1.04 M2026-06-30
Opaleye Management Inc.2.67%890 0002026-06-30
VANGUARD INDEX FUNDS-Van…2.09%697 8022026-06-30
Mackenzie Financial Corp…1.67%555 6762026-06-30
GSA Capital Partners LLP1.37%458 4722026-06-30
Shikiar Asset Management…0.92%305 4692026-06-30
Geode Capital Management…0.9%300 5212026-06-30
VANGUARD INDEX FUNDS-Van…0.84%279 8912026-06-30
Blackrock Inc.0.67%224 7822026-06-30
Two Sigma Investments, L…0.64%213 7862026-06-30
LOBELL JONAH JAY (Direct…≈0.58%192 3972025-12-31
Bridgeway Capital Manage…0.53%177 3682026-06-30
Vanguard Fiduciary Trust…0.5%166 3712026-06-30
Bridgeway Funds, Inc.-Ul…0.46%152 3682026-06-30
HARVEY JIMMIE (Director)≈0.44%146 7042025-12-31
Fidelity Concord Street…0.43%143 1832026-07-31
KLEIN DOV (Director)≈0.39%130 1052025-12-31
HOENLEIN MALCOLM (Direct…≈0.35%115 7472025-12-31
LORENZ KEVIN R. (Directo…≈0.3%101 0092025-12-31
iShares Trust-iShares Mi…0.26%86 9832026-07-31
LU LUCY (Director)≈0.18%61 2732024-12-31
Fidelity Concord Street…0.15%49 3202026-07-31
Fidelity Concord Street…0.11%35 8742026-07-31
EA Series Trust-EA Bridg…0.07%25 0002026-06-30
Fidelity Concord Street…0.06%18 5502026-07-31
VANGUARD Inst. INDEX Fd.…0.05%18 0512026-06-30